<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359774</url>
  </required_header>
  <id_info>
    <org_study_id>C10-56</org_study_id>
    <secondary_id>2011-A00137-34</secondary_id>
    <nct_id>NCT01359774</nct_id>
  </id_info>
  <brief_title>31P-MRS and Huntington Disease</brief_title>
  <acronym>PRO-MH</acronym>
  <official_title>31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify and quantify a brain energy deficit in Huntington
      patients, using 31P-RMN spectroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain energy deficit in Huntington patients</measure>
    <time_frame>one year</time_frame>
    <description>31P-MRS allows quantification of high-energy phosphate metabolites such as ATP and phosphocreatine.
Objective: to look at brain energy metabolism during rest and activation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients</measure>
    <time_frame>one year</time_frame>
    <description>Biochemical parameters include metabolites that we previously showed to be biomarkers in HD: branched chain amino acids and IGF1.
Clinical parameters include UHDRS and TFC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Huntington patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>31P-MR spectroscopy</intervention_name>
    <description>Brain energy deficit is quantified using 31P-MR spectroscopy</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>31P-RMN spectroscopy</intervention_name>
    <description>Brain energy deficit is quantified using 31P-RMN spectroscopy</description>
    <arm_group_label>Huntington patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  5&lt;UHDRS&lt;50

          -  Age&gt;18 years

          -  Ability to undergo MR scanning

          -  Covered by french social security

        Exclusion Criteria:

          -  Evidence of psychiatric disorder

          -  Attendant neurological disorder

          -  Contraindications to MRI (claustrophobia, metallic or material implants)

          -  Severe head injury

          -  Unable to understand the protocol

          -  Pregnancy

          -  Failure to give informed consent

          -  Subjects with exclusion criteria required by french law (e.g. subjects who require a
             legally authorized representative to obtain consent)

          -  Unwillingness to be informed in case of abnormal MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny Mochel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM UMR S975 Institut du Cerveau et de la Moelle, AP-HP Département de Génétique, Université Pierre et Marie Curie, Paris France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital de la Pitié-Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.euro-hd.net</url>
    <description>European Huntington's Disease Network</description>
  </link>
  <reference>
    <citation>Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011 Feb;121(2):493-9. doi: 10.1172/JCI45691. Epub 2011 Feb 1. Review.</citation>
    <PMID>21285522</PMID>
  </reference>
  <reference>
    <citation>Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One. 2007 Jul 25;2(7):e647.</citation>
    <PMID>17653274</PMID>
  </reference>
  <reference>
    <citation>Mochel F, Benaich S, Rabier D, Durr A. Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Arch Neurol. 2011 Feb;68(2):265-7. doi: 10.1001/archneurol.2010.358.</citation>
    <PMID>21320997</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Energy</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

